Evidence map›Paper›PMID 42037766›Full record

ArticleBio-protocol2026

A Feeder Cell-Free System for Chimeric Antigen Receptor Gene Transduction Into Natural Killer Cells.

Nobuhiro Kubo, Minori Baba, Yuko Suzuki, Yasushi Kasahara, Ryosuke Hosokai, Masaru Imamura, Akihiko Saitoh, Chihaya Imai

Abstract read
In one paragraph

Article in Bio-protocol, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nobuhiro KuboDepartment of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Minori BabaDepartment of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Yuko SuzukiDepartment of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Yasushi KasaharaDepartment of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Ryosuke HosokaiDepartment of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Masaru ImamuraDepartment of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Akihiko SaitohDepartment of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Chihaya ImaiDepartment of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-CD19 chimeric antigen receptor (CAR)-natural killer (NK) cells are expected to demonstrate anti-CD19 CAR-T-cell-like efficacy against relapsed and refractory B-cell malignancies and autoimmune diseases, with fewer adverse events and the added advantage of permitting the use of allogeneic cells. However, the methodology for generating CAR-NK cells remains under development. Although various cell sources and expansion methods are available, feeder cells derived from cancerous tissue have been most commonly employed to promote ex vivo expansion of NK cells. In the protocol described herein, NK cells are expanded from adult peripheral blood mononuclear cells using CD2- and NKp46-specific stimulating antibodies in combination with multiple cytokines. The activated NK cells can be genetically modified using a retroviral vector. Subsequent culture of these cells yields large numbers of anti-CD19 CAR-NK cells. The current method, which enables feeder-free, large-scale generation of anti-CD19 CAR-NK cells, eliminates the risk of tumor cell contamination and may facilitate safer clinical application. Key features • This method for expanding human primary NK cells ex vivo uses stimulatory antibodies and multiple cytokines, without requiring feeder cells, usually derived from cancerous tissue. • NK cells are selectively expanded from unsorted peripheral blood mononuclear cells. • Retroviral vector efficiently mediates gene transfer into NK cells stimulated with the current method. • Although the cells were not sorted, gene transfer into T cells is minimal.

Indexed as

Anti-CD2 antibodyAnti-NKp46 antibodyCAR-NK cellsInterleukin-12Interleukin-18Interleukin-21NK cell expansionOff-the-shelf

Identifiers

PMID42037766
PMCPMC13103968

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.